NAME

Question types


Start with


Question limit

of 30 available terms

Print test

5 Written questions

5 Matching questions

  1. Gemtuzumab
  2. DMARD clinical Uses
  3. NSAID Drugs
  4. Mycophenolate Mofetil
  5. Infliximab
  1. a prevention of acute allograft rejection
    Treatment of all inflammatory conditions
    Short-term anti-inflammatory
  2. b MOA: MMF converted in-vivo to mycophenolic acid
    Inhibits T/B cell proliferation
    Prevents DNA synthesis by inhibiting IMP-DH prevents guanosine nucleotide production
    Clinical Uses: Prevention of GVHD
    graft rejection
    Lupus nephritis
    Toxcities: Diarrhea, vomitting, nausea, meylosupression
    Contraindication: Hepatic Insufficiency
  3. c Leukemia/lymphoma therapy
    MOA: anti CD33 w/calicheamicin. Binds CD33+ cells Drug is internalized binds to DNA resulting in DNA double stranded breaks and cell death
  4. d Aspirin
    Ibuprophen
    Naproxene
    Celecoxib
  5. e TNF antagonist
    Immunosuppresant
    MOA: TNF targeting
    Clinical Uses: Crohns disease, RA, Ulcerative Colitis,

5 Multiple choice questions

  1. Leukemia/lymphoma therapy
    Conjugate
    MOA: IL2+Diptheria toxin fusion protein. Binds to IL2r+ cells
    Toxins prevent protein synthesis and cell death
    Clinical Uses: cutaneous T-cell Lymphoma
  2. inhibits transcription of inflammatory mediators
    Increase some anti-inflammatory regulator genes
    Decrease production of cytokines
    Reduced expression of adhesion molecules =decreased leukocyte adhesion
  3. Corticosteroid
    Immunosuppressant
    Long-action
    MOA: DMARD
    Tox: DMARD
  4. Calcineurin Inhibitor
    MOA: binds FK protein inhibits IL-2 Secretion and other cytokines
    Clinical Use: Prevention/Rejection of organ transplantation
    Toxcities: Nephrotoxic, Diabetes, peripheral neuropathy
  5. Inflammatory conditions
    Not for transplantation

5 True/False questions

  1. OmalizumabImmunosupressant
    MOA: IgE antagonist
    Clinical Uses: Asthma

          

  2. ChlorambucilmTOR inhibitor
    MOA: Inhibits T-cell proliferation
    binds FKBP-12 and inhibits mTOR pathway
    Blocks IL-2 signalling
    Clinical Uses: prevention of renal transplant rejection
    Adverse Effects: Nephrotoxicity, Hypercholestrolemia, Hyper triglyceridemia, mylosuppression

          

  3. SirolimusmTOR inhibitor
    MOA: Inhibits T-cell proliferation
    binds FKBP-12 and inhibits mTOR pathway
    Blocks IL-2 signalling
    Clinical Uses: prevention of renal transplant rejection
    Adverse Effects: Nephrotoxicity, Hypercholestrolemia, Hyper triglyceridemia, mylosuppression

          

  4. CyclophosphamideCalcineurin Inhibitor
    MOA: prevents IL2/IL-2 receptor production
    Clinical Uses: prevetion of graft rejection, not reverse graft rejection
    Tox: Reversible B-lympoproliferatie disorders, Nephrotoxic

          

  5. AzthioprineIL-1 cytokine antagonist
    Soluable Ligand Receptor Drugs
    MOA: sIL1 receptor antagonist
    Clinical Uses: RA